Opinions Rob Callander
Spectral Med IncEDT.TOBUYMar 29, 2004
A really neat little company. Good funding of their R&D. They have revenue and operating profits. Agreement with Cardinal will be good for getting tests done in US.
Rob CallanderUnknown
$2.96
Stock price when the opinion was issued
$1.36
As of Jun 23, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
WEAK BUY
Will have to see a development of their Test kits (?) and have been slow in coming.
Robert FloydOwned
biotechnologypharmaceutical
BUY
HOLD
Has been in the doldrums. They have to do a better job of marketing the company and letting investors know exactly what they're up to. Haven't had anything strong enough yet to move the company forward.
Robert FloydOwned
biotechnologypharmaceutical
